<DOC>
	<DOCNO>NCT01263886</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate progression free survival ( PFS ) improvement ombrabulin compare placebo , combination taxane platinum , first line treatment patient metastatic non-small cell lung cancer ( NSCLC ) . Secondary Objective : - To determine overall survival ( OS ) , overall response rate ( ORR ) accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion , safety , evaluate potential biomarkers , pharmacokinetic ( PK ) analysis ombrabulin main metabolite , RPR258063 , use population approach .</brief_summary>
	<brief_title>Trial Ombrabulin ( AVE8062 ) Combination With Taxane Platinum Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Patients treat maximum 6 cycle ( 21 day ) , absence unacceptable toxicity disease progression consent withdrawal . All patient follow disease progression documentation patient status one year primary analysis cutoff date .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Inclusion criterion : Histologically proven squamous metastatic nonsmall cell lung cancer ( stage IV , accord Tumor Nodes Metastasis ( TNM ) classification seventh edition ) Patients measurable disease , Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion ( version 1.1 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Exclusion criterion : Prior chemotherapy , immunotherapy target therapy lung cancer disease ( include adjuvant/neoadjuvant therapy ) History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis History another neoplasm . Adequately treat basal cell squamous skin cancer , situ cervical cancer , cancer patient diseasefree &gt; 5 year allow Participation another clinical trial concurrent treatment investigational drug within 30 day prior randomization Acquired immunodeficiency syndrome ( AIDSrelated illness ) know human immunodeficiency virus ( HIV ) disease require antiretroviral treatment Any severe acute chronic medical condition , could impair ability patient participate study interfere interpretation study result Pregnant breastfeed woman . Positive serum urine pregnancy test prior randomization Patient reproductive potential ( Male/Female ) agree use accept effective method contraception study treatment period least 3 month completion study treatment . The definition `` effective method contraception '' base investigator 's judgment Inadequate organ function Preexisting peripheral neuropathy &gt; grade 1 accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) V.4.03 Preexisting hear impairment &gt; grade 2 Known hypersensitivity due taxanes /or polysorbate 80 compound study drug combination Other serious illness medical condition ( restrict ) : Active infection , Superior vena cava syndrome , Pericardial effusion require intervention ( drainage ) Documented medical history myocardial infarction , document angina pectoris , arrhythmia especially severe conduction disorder second thirddegree atrioventricular block , stroke , history arterial venous thromboembolism within past 6 month still require anticoagulant . Uncontrolled hypertension within 3 month prior study treatment patient organ damage relate hypertension . Patient Left Ventricular Ejection Fraction ( LVEF ) value low institution inferior normal limit , evaluate echocardiography angiocardiography 12lead Electrocardiogram ( ECG ) : Infarction Qwave , ST segment depression elevation â‰¥1 mm least 2 contiguous lead History gross hemoptysis ( i.e . 1/2 teaspoon red blood per episode ) within past 1 month . Has nonsquamous NSCLC ( adenocarcinoma/large cell ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>